Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Grifols

Next Previous
X
Search
Drug Profile

Immune globulin - Grifols

Alternative Names: Flebogamma 10% DIF; Flebogamma 5% DIF; Flebogamma DIF; GamaSTAN; GamaSTAN S/D; GAMMAKED; Human normal immunoglobulin; IGSC 20% - Grifols; Immune Globulin Subcutaneous 20% Caprylate/Chromatography; Intravenous normal Human immunoglobulin – Grifols; IVIG - Grifols; Xembify; Xepol; XS-28

Latest Information Update: 31 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grifols
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postpoliomyelitis syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Guillain-Barre syndrome; Hepatitis A; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Measles; Rubella; Varicella zoster virus infections
  • Registered Mucocutaneous lymph node syndrome
  • Preregistration Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease
  • Phase III Liver cirrhosis
  • Phase II/III Alzheimer's disease; Postpoliomyelitis syndrome
  • Phase II COVID 2019 infections
  • Preclinical Dry eyes

Most Recent Events

  • 29 Jul 2024 Registered for Immunodeficiency disorders (Treatment-naive) in USA (SC)
  • 29 Jul 2024 Grifols plans to launch Immune globulin for Immunodeficiency disorders (Treatmey naive) in US (SC, 20%) in 3Q of 2024
  • 26 Jun 2023 Launched for Immunodeficiency disorders in Spain (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top